X0202 SCHEDULE 13G 0001039765 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 08/19/2026 0000034956 Tenax Therapeutics, Inc. 88032L605 101 Glen Lennox Drive, Suite 300 Chapel Hill NC 27517 Rule 13d-1(c) ING Groep N.V. P7 0 2639666 0 2639666 2639666 7.05 HC * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026. ING Capital Markets LLC DE 0 2639666 0 2639666 2639666 7.05 OO * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026. Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517, USA ING Groep, N.V. ING Capital Markets LLC ING Groep N.V. PO Box 1800 Amsterdam, P7 1000 BV Amsterdam ING Capital Markets LLC 1133 Avenue of the Americas New York, NY 10036 USA ING Groep N.V. - The Netherlands ING Capital Markets LLC - Delaware Y ING Groep N.V. may be deemed to be the beneficial owner of 2,639,666 Common Stock, held by ING Capital Markets LLC, a wholly owned subsidiary of ING Groep N.V. ING Capital Markets LLC may be deemed to be the beneficial owner of 2,639,666 Common Stock. Each of ING Groep N.V. and ING Capital Markets LLC may be deemed to be the beneficial owner of approximately 7.05% of Common Stock issued and outstanding as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026. 0 2639666 0 2639666 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. ING Groep N.V. /s/ Andreea Albu 08/27/2026 /s/ Ioana Adriana Barbu 08/27/2026 ING Capital Markets LLC /s/ Tyrel Tugade 08/27/2026 /s/ Anthony Masciangelo 08/27/2026